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Abstract
Background: Previous studies found an association between migraine and dementia, which are two leading causes
of disability. However, these studies did not differentiate between migraine types and did not investigate all
prevalent dementia subtypes. The main objective of this national register-based study was to investigate whether
migraine was a risk factor for dementia. Additionally, we explored potential differences in dementia risk for migraine
with and without aura.
Methods: We obtained data on birth cohorts born between 1935 and 1956 (n = 1,657,890) from Danish national
registers. Individuals registered with migraine before age 59 (n = 18,135) were matched (1:5) on sex and birthdate
with individuals without migraine (n = 1,378,346). Migraine was defined by International Classification of Diseases
(ICD) diagnoses and dementia was defined by ICD diagnoses and anti-dementia medication. After matching, 62,578
individuals were eligible for analysis. For the statistical analyses, we used Cox regression models and adjusted for
socio-demographic factors and several psychiatric and somatic morbidities.
Results: During a median follow-up time of 6.9 (IQR: 3.6–11.2) years, 207 individuals with migraine developed
dementia. Compared with individuals without migraine, we found a 50% higher rate of dementia among
individuals with migraine (HR = 1.50; 95% CI: 1.28–1.76). Individuals without aura had a 19% higher rate of dementia
(HR = 1.19; 95% CI: 0.84–1.70), and individuals with aura had a two times higher rate of dementia (HR = 2.11; 95% CI:
1.48–3.00).
Conclusions: Our findings support the hypothesis that migraine is a midlife risk factor for dementia in later life. The
higher rate of dementia in individuals with a hospital-based diagnosis of migraine with aura emphasizes the need
for studies on pathological mechanisms and potential preventative measures. Furthermore, given that only hospital-
based migraine diagnoses were included in this study, future research should also investigate migraine cases
derived from the primary healthcare system to include less severe migraine cases.
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Background
Migraine and dementia are among the most prevalent
neurological disorders and leading causes of disability
[1]. Whereas dementia is the most common neurological
syndrome in older adults [1, 2], migraine is the most
common neurological disorder across all ages [1, 3]. Pre-
vious epidemiological studies reported a positive associ-
ation between migraine and Alzheimer’s disease (AD),
vascular dementia (VaD) and unspecified dementia [4–
8]. However, the majority of these studies are based on
smaller populations and without a clear temporal separ-
ation of migraine and dementia [4, 5, 7, 8]. Other studies
investigating the association between migraine and cog-
nitive dysfunction have reported mixed results, which
can be due to differences in study design, methodology
and study population type and size [9]. The exact patho-
physiological links between migraine and dementia are
unknown, but mechanisms may include vascular disease
and changes, increased amyloid plaque formation, in-
flammation, and deficits in nerve growth factors due to
comorbid depression, increased cortisol levels due to
psychological stress, brain structural changes in overlap-
ping pain and memory networks [10], cardiovascular-
and cerebrovascular events due to stroke and myocardial
infarction [11], and structural brain abnormalities [12].
Migraine is a complex disorder characterized by epi-
sodes of severe, often unilateral throbbing or pulsating
headache associated with multiple symptoms such as
nausea, photophobia, and phonophobia [13]. Up to 1/3
of individuals with migraine experience aura character-
ized by reversible transient neurological symptoms, typ-
ically preceding the headache [14]. In particular,
migraine with aura (MA) is observed to have a stronger
association with structural brain abnormalities [12]. Yet,
the specific effects of MA and migraine without aura
(MO) in relation to a more comprehensive outcome
measure of dementia have not been investigated.
Since brain changes indicative of cerebral small vessel
disease increase the risk for most dementia types and
cerebrovascular dysfunction [15], it is possible that the
vascular component of migraine contribute to the risk of
dementia [16]. Yet, due to the long preclinical phase of
dementia [2, 17], the lack of substantial temporal separ-
ation of migraine and dementia in previous studies in-
creases the risk of reverse causation, i.e., that early
dementia-related vascular changes lead to migraine. To
assess clinically relevant associations between migraine
and dementia, longitudinal and population-based studies
with larger samples are needed [18].
In this longitudinal population-based register study,
the main objective was to investigate whether migraine
registered in midlife was a risk factor for dementia in
later life. Secondary objectives were to investigate
whether MO and MA affected the risk of dementia, and
to explore potential dose-response relations between mi-
graine severity and dementia risk as well as differences
across sex and educational level.
Methods
Study population and design
We used national register-based data on all inhabitants in
Denmark of all ethnic origins born between 1935 and
1956 (N = 1,657,890), and the study covered 30 calendar
years (1988–2017). Individuals registered with their first
migraine diagnosis at age 31–58 were included. Individ-
uals were considered at dementia risk at age ≥ 60 due to
lower validity of dementia diagnoses in patients younger
than 60 years [19, 20]. Because migraine diagnosis criteria
was defined with the establishment of the International
Classification of Headache Disorders (ICHD) in 1988 [21]
and since incorporated in the International Classification
of Diseases (ICD) [22], migraine information was included
from 1988 to increase exposure assessment validity. We
followed individuals in registers until being registered with
dementia, death, emigration, or end of follow-up in 2017,
whichever occurred first (Fig. 1).
Individuals were excluded if they died, emigrated or
were registered with dementia before age 60, or due to
missing information on covariates (Fig. 2). Lack of full
coverage of register information on educational level
and marital status [23] led to the exclusion of a substan-
tial proportion of individuals, who were otherwise eli-
gible for inclusion (n = 42,786; median age at index year:
35, IQR: 30–40; 70% women).
We used an exposure-matching procedure [24] based
on sex and birthdate (± 30 days) to match sets of one in-
dividual with migraine with five individuals without mi-
graine. All had to be alive on their 60 years’ birthday to
be followed for incident dementia. In each matched set,
we used the date of the migraine diagnosis to define an
index year for all 6 individuals. This index date was used
when retrieving information about covariates (see para-
graph on covariates). The final study population in-
cluded 62,578 individuals.
Migraine
Migraine diagnoses were obtained from 1988 onwards
from the Danish National Patient Register and the Da-
nish Psychiatric Central Research Register, which in-
clude information on diagnoses registered by the
secondary healthcare system, when an individual has
been in contact with any hospital department due to in-
patient, outpatient, or emergency room visits [25, 26].
Migraine was defined as first ever registration with one
of the following migraine diagnoses: hemicrania ophthal-
moplegica (ICD-8: 346.00), hemicrania alia definita
(ICD-8: 346.08), hemicrania (ICD-8: 346.09); migraine
(ICD-10: G43), MO (ICD-10: G43.0), MA (ICD-10:
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G43.1), status migrainosus (ICD-10: G43.2), complicated
migraine (ICD-10: G43.3), other migraine (ICD-10:
G43.8), or unspecified migraine (ICD-10: G43.9). First,
we created one migraine variable defining individuals
registered with any migraine diagnosis (none/any mi-
graine diagnosis). Second, to investigate potential differ-
ences between MO and MA, we created a variable
categorizing migraine into MO, MA and all other ICD-8
and ICD-10 migraine diagnoses (none/MO/MA/all other
migraine diagnoses). Finally, we did an additional refine-
ment of migraine to investigate migraine severity. We
defined a migraine contact variable based on the total
number of registered hospital contacts with migraine as
primary diagnosis for contact before age 59 (range: 1–43
Fig. 1 Study design. Birth cohorts born between 1935 and 1956 are illustrated from 1988 to 2017. Individuals were followed from when they
turned 60 years until death, emigration, dementia diagnosis, or end of follow-up in 2017. Migraine diagnoses were registered from 1988 onwards.
This figure illustrates the life course of a single individual from 6 of the 21 included birth cohorts exemplifying individuals turning 60 years and
being followed in registers until endpoints
Fig. 2 Flow chart of the study population selected for analyses (N = 62,578). Data were obtained on 1,657,890 inhabitants in Denmark born
between 1935 and 1956. After excluding individuals due to missing information, migraine after age 58, or dementia, death or emigration before
entry, 18,135 individuals with migraine diagnoses were matched with 1,378,346 individuals without migraine diagnoses. The matched study
population consisted of 105,364 individuals, but also included individuals without information on education and marital status for specific index
years and these individuals were therefore excluded after matching leaving 62,578 individuals eligible for analysis
Islamoska et al. The Journal of Headache and Pain           (2020) 21:98 Page 3 of 12
contacts; migraine cases: 8551; categories: 0/1/2/≥ 3 mi-
graine contacts). Among individuals with migraine, we
also investigated the rate of dementia when having more
hospitals contacts due to other morbidities with mi-
graine registered as secondary diagnosis at the same
time (range: 1–51 contacts; migraine cases: 10,857). A
hospital contact variable was defined identically to the
migraine contact variable.
Dementia
Dementia was defined as the first ever registration with
dementia diagnosis or first redeemed anti-dementia
medication, whichever came first. Data on dementia
diagnoses were based on data from the Danish National
Patient Register [25], Danish Psychiatric Central Re-
search Register [26], and Danish Register of Causes of
Death [27] by ICD codes from ICD-8 and ICD-10: un-
specified dementia, AD, VaD, frontotemporal dementia,
and Lewy body dementia (Table 1). In Denmark, national
clinical guidelines for diagnosing dementia include stand-
ard diagnostic procedures, such as cognitive, neurological
and mental assessment, neuroimaging, and laboratory
tests [28]. Data on first redeemed prescriptions of anti-
dementia medications were based on Anatomical Thera-
peutic Chemical (ATC) codes for cholinesterase-inhibitors
of Donepezil (ATC: N06DA02), Rivastigmine (ATC:
N06DA03), Galantamine (ATC: N06DA04), and the
glutamate-receptor antagonist Memantine (ATC:
N06DX01) obtained from the Danish National Prescrip-
tion Registry [29]. Dementia patients in Denmark can re-
ceive a prescription for anti-dementia medication from all
medical doctors, but only receive reimbursement when
prescribed by a specialist in geriatrics, neurology or psych-
iatry [30]. Indications for using the glutamate-receptor an-
tagonist Memantine in migraine treatment have been
suggested [31], however, in Denmark, Memantine is only
approved for dementia treatment [32].
Covariates
Information on all covariates was extracted from na-
tional registers 1 year before the index year in order to
ensure that these potential confounders were assessed
before the exposure (i.e., migraine status). We included
information on socio-demographic factors, such as birth-
date, sex, country of origin (Denmark/Western coun-
tries/Non-Western countries) [33], marital status
(unmarried/married), highest educational level [2] (low
educational level defined by primary school/medium
educational defined by upper secondary education, busi-
ness high school, and vocational education and training/
high educational level defined by short-term further edu-
cation, middle-range education, bachelor’s degree, ex-
tended education, and research degree).
Headache diagnoses occurring before migraine diagno-
sis included: cephalalgia, other headache syndromes,
cluster headache syndrome, vascular headache, tension-
type headache, chronic post-traumatic headache, drug-
induced headache, and other specified headache
syndromes (Table 1).
We included information on psychiatric diagnoses oc-
curring before migraine diagnosis as follows: schizophre-
nia, schizotypal and delusional disorders, mood affective
disorders, psychoses, neuroses, and transient situational
disturbances (Table 1).
To adjust for different morbidities potentially associated
with migraine and dementia, we adjusted for multimor-
bidity defined by the Charlson Comorbidity Index (CCI)
[34, 35]: myocardial infarction, heart failure, peripheral
vascular disease, cerebrovascular disease, pulmonary dis-
ease, connective tissue disorder, peptic ulcer, liver disease,
diabetes, diabetes complications, paraplegia, renal disease,
cancer, metastatic cancer, severe liver disease, and human
immunodeficiency virus (Table 1). Migraine may coexist
with some of the included morbidities, or some morbid-
ities could be consequences of migraine. In the present
study, we treated morbidities as potential confounders,
i.e., we adjusted for morbidities registered before the mi-
graine diagnosis (or the index date for individuals without
a migraine diagnosis). The purpose of including CCI was
to adjust for multimorbidity, thereby, adjusting for some
of the common risk factors for migraine and dementia,
but also to take into account the health status of individ-
uals with and without migraine.
All data in this study were obtained with approval
from Statistics Denmark and the Danish Health Data
Authority.
Statistical analyses
Using frequency analyses, we investigated the distribu-
tion of socio-demographic factors, headache, psychiatric
morbidities and CCI among individuals with and with-
out migraine.
The Cox regression model was used to investigate the
association between migraine and dementia. We calcu-
lated hazard rate ratios (HR) of dementia and used age
as the time scale beginning at age 60. As we used data
from individuals born across a wide year range and the
probability of exposure misclassification depends on
birth cohort, we stratified analyses on birth cohort to en-
sure that comparisons were made among individuals
with the same probability of misclassification of
exposure.
First, we investigated the association between any mi-
graine diagnosis and dementia by using an overall mi-
graine variable including all migraine diagnoses. We
adjusted for potential confounders using two models:
Model 1 included sex; and Model 2 included sex,
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Table 1 Diagnostic codes for dementia and included covariates from the International Classification of Diseases
Type of diagnoses ICD-8 codes ICD-10 codes
Dementia
Alzheimer’s disease 290.10 F00.0–00.9, G30.0–30.9
Vascular dementia 293.09–19 F01.0–01.9
Frontotemporal dementia 290.11 F02.0
Lewy body dementia G31.8
Unspecified and other dementia 290.09, 290.18–19 F03.9, G31.9
Headache
Cephalalgia 791.99 DR51, DR519
Other headache syndromes G44
Cluster headache syndrome G44.0
Vascular headache G44.1
Tension-type headache G44.2
Chronic post-traumatic headache G44.3
Drug-induced headache G44.4
Other specified headache syndromes G44.8
Psychiatric
Schizophrenia, schizotypal and delusional
disorders
295.09–99, 297.09–99 F20-F29
Mood affective disorders 296.09–99, 790.29 F30-F39
Other or unspecified psychoses 298.09–99, 299.00–09
Neuroses 300.49–99
Transient situational disturbances 307.99
Acute stress reactions F43.0
Post-traumatic stress disorders F43.1
Adjustment disorders F43.2
Other stress reactions F43.8
Unspecified stress reactions F43.9
Charlson Comorbidity Index
Myocardial infarction 410 I21, I22, I23
Heart failure 427.09, 427.10, 427.11, 427.19, 428.99, 782.49 I50, I110, I130, I132
Peripheral vascular disease 440, 441, 442, 442, 444, 445 I70, I71, I72, I74, I77
Cerebral vascular accident 430–438 I60-I69, G45, G46
Pulmonary disease 490–493, 515–518 J40-J47, J60-J67, J684, J701, J703. J841, J920, J961,
J982, J983
Connective tissue disorder 712, 716, 734, 446, 135.99 M05, M06, M08, M09, M30, M31, M32, M33, M34,
M35, M36, D86
Ulcer disease 530.91, 530.98, 531–534 K221, K25-K28
Mild liver disease 571, 573.01, 573.04 B18, K700–703, K709, K71, K73, K74, K760
Diabetes 249.00, 249.06, 249.07, 249.09, 250.00, 250.06,
250.07, 250.09
E100, E101, E109, E110, E111, E119
Hemiplegia 334 G81, G82
Renal disease 403, 404, 580–584, 590.09, 593.19, 753.10, 753.20,
792
I12, I13, N00, N06, N07, N11, N14, N17-N19, Q61
Diabetes with complications 249.01–249.05, 249.08, 250.01–250.05, 250.08 E102-E108, E112-E118
Cancer 140–194 C00-C75
Leukemia 204–207 C91-C95
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country of origin, marital status, educational level, head-
ache, psychiatric morbidities, and CCI. Second, we inves-
tigated the associations of MO and MA with dementia and
adjusted for covariates in Models 1 and 2. Furthermore, we
investigated migraine severity by using the migraine contact
variable as exposure in relation to dementia adjusting for co-
variates in Models 1 and 2. Similarly, we also investigated the
association between several hospital contacts among individ-
uals with migraine and dementia. Individuals without mi-
graine were the reference group in all analyses.
We also examined interactions between migraine and sex
and educational level, respectively, on the rate of dementia
by adding interaction terms to the Cox regression model.
To ensure the temporal relation between migraine and
dementia, we strictly separated the timing of migraine and
dementia by performing sensitivity analyses in which we
postponed the start of follow-up with at least 5, 10, 15,
and 20 years after the index date. This was done in order
to reduce the risk of reverse causation, i.e., that the risk of
migraine was affected by underlying cerebrovascular
mechanisms of dementia, since dementia can have a long
preclinical phase starting already in midlife [17].
The Cox regression model assumes that the ratio of
hazards for any two groups is constant over time [36],
therefore, the proportionality of hazards was tested. By
using a Cox regression model including covariates of
Model 2, we tested the significance of a time dependent
interaction between time and covariates [37]. We con-
sidered p-values < 0.05 as statistically significant.
We used SAS Enterprise Guide version 7.1 in combin-
ation with SAS 9.4 to conduct all analyses.
Results
In this national register-based follow-up study, 18,135
were registered with migraine and of those, 10,857 were
eligible for inclusion. After matching, the study popula-
tion included 62,578 individuals (Fig. 1). Median age at
index year was 49 years, and approximately 70% were
women. The cohort with any migraine did not differ
substantially from the comparison cohort (Table 2).
During a median follow-up time of 6.9 years (inter-
quartile range (IQR): 3.6–11.2) from age 60 years, 207
individuals with migraine were identified as dementia
cases at a median age of 68 years (IQR: 64–73). Among
individuals without migraine, 640 individuals had de-
mentia at a median age of 69 years (IQR: 65–73). The
median time between registered migraine and dementia
was 18.3 years (IQR: 13.4–22.7) and the total follow-up
time was 30 years from 1988 to 2017. Individuals were
primarily registered with dementia in patient data (82%),
then prescription data [17], and mortality data (1%).
Individuals with migraine had a 1.50 times higher rate of
dementia (95% CI: 1.28–1.76). Individuals with MO had a
1.19 times higher rate of dementia (95% CI: 0.84–1.70), and
individuals with MA had a 2.11 times higher rate (95% CI:
1.48–3.00). There was a significant difference between the
rates of dementia for MO and MA (p = 0.02). All other mi-
graine types, excluding MO and MA, were associated with
a 1.48 times higher rate of dementia (95% CI: 1.23–1.78).
We found a 1.38 times higher rate of dementia for individ-
uals with one migraine contact (95% CI: 1.13–1.69), and a
1.51 times higher rate when having two contacts (95% CI:
1.01–2.27) compared with individuals without migraine.
Among individuals with migraine, the rate of dementia was
1.49 times higher (95% CI: 1.25–1.77) when having one
hospital contact, and 1.80 times higher (95% CI 1.29–2.51)
with two hospital contacts. Due to a low number of demen-
tia cases among individuals with ≥ 3 migraine and hospital
contacts, these results are probably not reliable (Table 3).
Sensitivity analyses showed that the magnitude and dir-
ection of the association between having any migraine,
MO, MA and other types of migraine and dementia
remained when including different time intervals between
migraine and start of follow-up (at least 5, 10, 15 and 20
years between index date and start of follow-up) (Table 3).
Interaction analyses showed a slightly higher rate of demen-
tia in women with migraine than in men with migraine, and a
higher rate was also observed in individuals with a higher edu-
cational level than in other educational levels. However, these
differences were not statistically significant (Table 4).
The assumption of proportional hazards could not be
rejected, thus, the overall rate of dementia for any mi-
graine did not vary significantly with time after age 60.
Discussion
Main results
We observed a higher rate of dementia after age 60
among individuals with migraine in midlife compared
Table 1 Diagnostic codes for dementia and included covariates from the International Classification of Diseases (Continued)
Type of diagnoses ICD-8 codes ICD-10 codes
Lymphoma 200–203, 275.59 C81-C85, C88, C90, C96
Severe liver disease 070.00, 070.02, 070.04, 070.06, 070.08, 573.00,
456.00–456.10
B150, B160, B162, B190, K704, K72, K766, I85
Metastatic cancer 195–199 C76, C81
HIV 079.83 B21-B24
ICD International Classification of Diseases of the 8th (ICD-8) and 10th version (ICD-10)
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with individuals without migraine. MA was associated
with the highest rate of dementia. The rate of dementia
was higher among individuals with more hospital regis-
trations of migraine. The observed associations did not
change substantially when taking several confounders
into account, or including longer time between registra-
tion of migraine and dementia.
Comparison with previous research
Our findings are comparable with other studies report-
ing an association between both self-reported [7, 8] and
clinically diagnosed migraine [4–6] and a higher risk of
dementia. In addition, our findings are also supported by
previously suggested plausible pathological mechanisms
between migraine and dementia [10].
Among individuals with migraine, a three times higher
risk has been reported for VaD [8] and all-cause demen-
tia [7], and a four times higher risk of AD [7]. In one of
these studies, individuals were on average 75 years when
reporting migraine history [7], thus, reverse causation
can be an issue. Other studies did not find an association
between migraine and cognitive decline [18] or dementia
[38]. These disparities could potentially be due to meth-
odological characteristics, e.g. the inclusion of individ-
uals reporting migraine at an older age, using too short
follow-up, including self-reported migraine, recalling mi-
graine history when having impaired cognitive function,
and possible difficulties in identifying small changes in
cognitive functioning despite the use of standardized
measurement methods [18]. A review concluded that
small sample sizes and limited information on migraine
characteristics, such as attack frequency, could be rea-
sons for not finding an association between migraine
and cognitive decline [18], which could also be the ex-
planation for not observing an association between mi-
graine and dementia [38]. Migraine attacks have shown
to be associated with poor cognitive performance
compared with headache-free periods [9]. However,
Table 2 Baseline characteristics of the study population based on migraine diagnoses shown in prevalence and medians (N =
62,578)
Any ICD-8 and ICD-10 migraine
diagnosis
Comparison
cohort
Any ICD-8
migraine
diagnosis
Any ICD-10
migraine
diagnosis
Migraine without
aura in
ICD-10
Migraine with
aura in
ICD-10
Characteristics n = 10,857 (17%) n = 51,721 (83%) n = 2183 (20%) n = 8674 (80%) n = 2845 (26%) n = 1698 (16%)
Age, median (IQR)
Years 49 (44–53) 49 (44–53) 43 (38–47) 50 (46–54) 50 (46–54) 51 (47–54)
Sex, No. (%)
Women 7975 (73) 38,104 (74) 1574 (72) 6401 (74) 2239 (79) 1200 (71)
Country of origin, No. (%)
Danish 10,087 (93) 49,177 (95) 2118 (97) 7970 (92) 2615 (92) 1586 (93)
Western 272 (2) 1399 (3) 35 (2) 237 (3) 76 (3) 55 (3)
Non-
Western
498 (5) 1145 (2) 31 (1) 467 (5) 154 (5) 57 (3)
Marital status, No. (%)
Unmarried 3029 (28) 15,027 (29) 566 (26) 2,463 (28) 824 (29) 432 (25)
Educational level, No. (%)
Low 3799 (35) 17,757 (34) 976 (45) 2,823 (32) 904 (32) 530 (31)
Medium 4173 (38) 20,366 (40) 814 (37) 3359 (39) 1089 (38) 656 (39)
High 2885 (27) 13,598 (26) 394 (18) 2492 (29) 852 (30) 512 (30)
Previous headache diagnoses, No. (%)
Yes 600 (6) 524 (1) 63 (3) 537 (6) 210 (7) 86 (5)
Previous psychiatric diagnoses, No. (%)
Yes 748 (7) 2185 (4) 126 (6) 622 (7) 191 (7) 115 (7)
Charlson Comorbidity Index, No. (%)
0 10,059 (93) 48,729 (94) 2135 (98) 7925 (91) 2,577 (91) 1542 (91)
≥1 789 (7) 2992 (6) 49 (2) 749 (9) 268 (9) 156 (9)
Migraine contacts, median (IQR)
Number 1 (1–2) – 1 (1–1) 1 (1–2) 1 (1–2) 1 (1–2)
ICD International Classification of Diseases 8th (ICD-8) and 10th version (ICD-10), IQR interquartile ranges
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different studies have shown conflicting results re-
garding the association between migraine and risk of
cognitive decline [9], and it is debatable whether
migraine-related cognitive complaints during attacks
would qualify for a diagnosis of mild cognitive
impairment.
Other studies using migraine based on ICD-9 and ICD-
10 found similar or somewhat lower dementia risks
compared with our study [4–6]. Two studies considered
individuals at dementia risk after age 60 [4, 5], however,
one of these studies retrieved information on migraine
and dementia simultaneously in the age range 60–80 years
[4]. This yields a potential overestimation of the associ-
ation between migraine and dementia due to the risk of
reverse causation or shared underlying causes. We
accounted for potential reverse causation by strictly separ-
ating timing of exposure from outcome and only included
migraine cases before age 59 and dementia cases after age
60. Sensitivity analyses were also conducted to assess the
degree of bias due to reverse causation.
Compared with MO, MA is associated with a higher
risk of structural brain abnormalities and cardio- and
cerebrovascular events [11, 12]. In our study, individuals
with MA had the highest rate of dementia, which is in
line with previous research supporting potentially stron-
ger vascular mechanisms in MA [11, 12]. Our findings
add to the knowledge on severe long-term consequences
of especially MA. To fully assess the impact of MO and
MA and later brain health, potentially modifying factors
as attack frequency and treatment should be included.
Strengths and limitations
This is the first national register-based study investigat-
ing hospital-based migraine diagnoses in midlife and de-
mentia risk in later life. Information on covariates dated
back to 1958, migraine dated back to 1988 and follow-
up lasted until 2017 with a low risk of loss to follow-up.
Compared with other studies using register-based mi-
graine information, we included all ICD-8 and ICD-10
diagnoses of migraine. We took into account potential
confounding of other headache diagnoses as well as sev-
eral different morbidities prior to migraine diagnosis.
Still, the results did not change substantially. Based on
the large population size, we were able to use an
Table 3 Hazard rate ratios of dementia associated with migraine diagnoses (N = 62,578)
Analysis Migraine diagnosis No. of
individuals
Minimum follow-up
years between
migraine and dementia
Dementia cases/
person-years
Model 1
HR
(95% CI)
Model 2
HR
(95% CI)
Main analysis None 51,721 ≥ 1 640/402,006 1.00 1.00
Any 10,857 ≥ 1 207/83,926 1.55 (1.32–1.81) 1.50 (1.28–1.76)
Migraine without aura 2845 ≥ 1 34/19,995 1.21 (0.85–1.72) 1.19 (0.84–1.70)
Migraine with aura 1698 ≥ 1 33/11,604 2.13 (1.50–3.03) 2.11 (1.48–3.00)
All other migraine types 6314 ≥ 1 140/52,328 1.55 (1.29–1.86) 1.48 (1.23–1.78)
Sensitivity analysis Any 10,773 ≥ 5 205/81,326 1.55 (1.32–1.81) 1.50 (1.28–1.76)
Any 10,198 ≥ 10 185/74,055 1.49 (1.26–1.75) 1.43 (1.21–1.69)
Any 9677 ≥ 15 174/69,486 1.53 (1.29–1.82) 1.48 (1.25–1.76)
Any 9271 ≥ 20 164/67,344 1.57 (1.32–1.87) 1.53 (1.28–1.83)
Additional refinement
of exposure
Number of contacts
Migraine contactsa 0 40,718 ≥ 1 499/313,832 1.00 1.00
1 6233 ≥ 1 121/50,101 1.44 (1.18–1.76) 1.38 (1.13–1.69)
2 1428 ≥ 1 25/10,432 1.63 (1.09–2.43) 1.51 (1.01–2.27)
≥ 3 890 ≥ 1 6/5438 0.94 (0.42–2.11) 0.89 (0.40–2.00)
Hospital contactsb 0 51,721 ≥ 1 640/402,006 1.00 1.00
1 7836 ≥ 1 162/63,184 1.53 (1.29–1.82) 1.49 (1.25–1.77)
2 1810 ≥ 1 37/13,305 1.89 (1.36–2.64) 1.80 (1.29–2.51)
≥ 3 1211 ≥ 1 8/7437 0.92 (0.46–1.85) 0.89 (0.44–1.79)
Model 1: adjusted for sex. Model 2: adjusted for sex, country of origin, marital status, educational level, headache diagnoses, psychiatric morbidities and Charlson
Comorbidity Index (CCI)
HR Hazard rate ratios, 95% CI 95% confidence intervals
a Analyses of migraine contacts and dementia were based on individuals with any migraine diagnosis registered as the primary reason for hospital
contact (N = 49,269)
b Analyses of hospital contacts and dementia were based on individuals with any migraine diagnosis registered as either primary or secondary reason for hospital
contact (N = 62,578)
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exposure-matching procedure and match one individual
with migraine with five individuals without migraine.
We examined migraine severity and our findings
highlighted the importance of monitoring severe
migraine.
Based on national recommendations by the Danish
Health Authority, uncomplicated migraine cases should
be treated by their own general practitioner, while com-
plicated, unsolved or rare migraine cases should be
treated by specialized neurologists or headache units
[39]. As we only included migraine cases treated in hos-
pital settings, we assume that the less severe and well-
managed migraine cases treated by general practitioners
are likely to be misclassified as non-exposed in our
study. This may lead to an underestimation of the
migraine-dementia association. In addition, the general
migraine prevalence is 16% in Denmark [40], while the
prevalence in our study was 1.3% (18,135 hospital-based
migraine cases out of 1,396,481 individuals), which also
yields a potential underestimation of the actual dementia
risk. Still, including only severe hospital-diagnosed mi-
graine cases may overestimate the observed association
between migraine and dementia. Hospital-based mi-
graine diagnoses may be associated with more complica-
tions, e.g. migraine chronification or medication overuse.
Compared with episodic migraine, individuals with
chronic migraine are observed to have more cognitive
impairment [41]. Furthermore, a review found that indi-
viduals with complicated medication overuse headache
(MOH) have better outcomes after inpatient treatment
indicating that cases of MOH may be inclined to seek
hospital treatment [42]. This suggest that migraine cases
with hospital-based diagnoses may include more severe
or complicated cases. Thus, our findings of a higher de-
mentia risk are only generalizable to individuals with se-
vere migraine requiring hospital contact and do not
necessarily apply to less severe migraine cases.
Some research suggests that migraine is a progressive
disorder due to being associated with later cardio- and
cerebrovascular events [11]. However, since migraine
may as well remit over time [3], we cannot preclude that
the included migraine cases may comprise individuals
with remitted migraine, which can lead to an underesti-
mation of the migraine-dementia association. We ac-
knowledge that there is individual variation in patients’
burden of migraine and, thereby, also later vascular brain
changes, which may depend on disease duration, attack
frequency, and type of migraine [12].
Another limitation is that age at first hospital contact
with migraine may not correspond with age at disease
onset. Migraine is most prevalent in the age group 25 to
55 years [3], while the median age of individuals when
registered with a migraine diagnosis was 49 years in our
population. Based on diagnostic criteria of migraine,
Table 4 Hazard rate ratios of dementia associated with migraine diagnoses grouped by sex or educational level (N = 62,578)
Characteristics No. of individuals Dementia cases/person-years HR (95% CI) P value for interaction
Sex 0.6a
Men
Without migraine 13,617 186/102,687 1.00
With migraine 2882 57/21,913 1.39 (1.03–1.88)
Women
Without migraine 38,104 454/299,319 1.00
With migraine 7975 150/62,013 1.54 (1.28–1.86)
Educational level 0.8b
Low
Without migraine 17,757 292/147,296 1.00
With migraine 3799 92/31,028 1.47 (1.16–1.87)
Medium
Without migraine 20,366 229/159,620 1.00
With migraine 4173 72/32,484 1.45 (1.11–1.89)
High
Without migraine 13,598 119/95,090 1.00
With migraine 2885 43/20,414 1.64 (1.16–2.33)
In all models, any migraine diagnosis was investigated as exposure. All models were adjusted for sex, all other migraine diagnoses, country of origin, marital
status, educational level, other headache diagnoses, psychiatric morbidities and Charlson Comorbidity Index
HR Hazard rate ratios, 95% CI 95% confidence intervals
a Interaction tested between migraine and sex
b Interaction tested between migraine and educational levels
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migraine is defined as a primary headache, which is not
caused by another disorder [13]. However, migraine is a
complex disorder and especially for MA, the diagnostic
challenges when discriminating between strokes, syn-
cope, seizure and MA [43] may delay the diagnosis and
thereby the time of registration in hospital data. Further-
more, the completeness of migraine ascertainment in
the National Patient Register may have changed over
time, since outpatient data were only included from
1995, and the inclusion of data from private hospitals
were not obligatory until 2003 [25]. In addition, when
restricting our population to migraine cases registered
from 1988 onwards in order to increase the validity of
migraine diagnoses, we also excluded individuals, who
might have been registered with migraine before age 31.
Our results are strengthened by using validated dementia
diagnoses from patient registers [44]. Yet, 60% of dementia
patients are not diagnosed [45], therefore, register data
underestimate the dementia prevalence. For a more com-
prehensive detection of individuals with dementia, both
register-based dementia diagnoses and prescriptions were
included. However, we cannot rule out that individuals with
more hospital contacts (e.g., due to migraine) are more
likely to be registered with dementia, even if their true de-
mentia risk is not higher. This detection bias would yield
an overestimation of the association between migraine and
dementia, which was partly addressed by adjusting for mul-
timorbidity. However, the registration of morbidity diagno-
ses in registers may not reflect the actual onset of disease,
as they may have existed for a longer time before actual
diagnosis. Furthermore, despite adjusting for numerous
confounders, dementia risk might be influenced by lifestyle
risk factors, medication, or other neurological disorders [3].
In addition, since the number of dementia cases was low
particularly among individuals with ≥ 3 migraine or hospital
contacts including only 6 and 8 dementia cases respectively,
this limits the validity of these specific analyses.
The oldest individuals were 82 years old at end of
follow-up. Therefore, including older individuals could
lead to different results, since dementia is an age-related
syndrome with typical onset starting from 80 to 89 years
[46]. Thus, our study population is at lower risk of de-
mentia diagnosis and death in general.
Some anti-migraine medications as ergotamines and
triptans have vasoactive actions [47]. Previous research
showed that triptans were not associated with ischemic
complications and vascular events [48, 49]. Treatment
with ergot alkaloids in migraine cases has not been veri-
fied as a stroke risk factor, but high ergotamine con-
sumption is possibly associated with risk of serious
ischemic complications [48]. Current evidence does not
suggest that the most used anti-migraine medication,
triptans, increase the risk of cardiovascular events [47].
Therefore, anti-migraine medication does not seem to
be a potential pathway to dementia. In terms of non-
steroidal anti-inflammatory drugs (NSAIDs), which are
also used in migraine treatment [50], a meta-analysis re-
ported that individuals using NSAIDs seemed to have a
lower risk of AD [51]. Yet, a review concluded that there
were no significant benefits of NSAIDs in the treatment
of AD [52], thus, the literature is inconclusive regarding
NSAID and its effect on dementia.
Conclusions
In conclusion, our results support the hypothesis that
migraine in midlife is a risk factor for dementia in later
life, especially for individuals with MA. It is conceivable
that some traits in certain individuals with migraine may
entail a more pronounced dementia risk. Frequent hos-
pital visits resulted in a higher rate of dementia. How-
ever, given the limitations of this study, we cannot
conclude on the dementia risk among individuals with
migraine treated outside hospitals. Future research
should preferably include individuals with migraine reg-
istered in both the primary and secondary healthcare
system to be able to investigate mild, moderate and se-
vere migraines and dementia risk. Our findings
emphasize the need for studies on the pathophysiology
linking migraine with dementia in order to identify pre-
ventive measures.
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